Report: Obesity, diabetes, high blood pressure remain on the rise in U.S.
Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...
Hosted on MSN3d
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
pharmaphorum4d
Social media advocacy: Healthcare professionals and the Treat and Reduce Obesity Act
The story of HCPs’ advocacy for the Treat and Reduce Obesity Act reveals a broader truth: HCPs care deeply about the ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
BioPharma Dive11d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Times Colonist13d
Obesity won't be solely defined by BMI under new plan for diagnosis by global experts
A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial body mass index and hoping to better identify people who need treatment ...
Manila Bulletin14d
Obesity won't be solely defined by BMI under new plan for diagnosis by global experts
A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial body mass index and hoping to better identify people who need treatment for ...